EC Ophthalmology

The global prevalence of myopia, especially among children, is rising at an alarming rate. This article examines the factors contributing to this trend, such as genetic and environmental influences, and highlights innovative treatments including orthokeratology and low-dose atropine. With an emphasis on data and evidence from recent studies, the article aims to provide a comprehensive overview of the current state of pediatric myopia and emerging solutions. The role of myopia management in preventing long-term ocular complications is also discussed.

 Keywords: Myopia; Children; Orthokeratology; Atropine

1. Holden BA., et al. “Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050”. Ophthalmology5 (2016): 1036-1042.
2. Wu PC., et al. “Epidemiology of myopia”. Asia-Pacific Journal of Ophthalmology6 (2016): 393-398.
3. Saxena R., et al. “Prevalence of myopia and its risk factors in urban school children in Delhi: The North India Myopia Study (NIM Study)”. PLoS ONE2 (2015): e0117349.
4. Morgan I and Rose K. “Myopia: Is the nature versus nurture debate finally over?” Clinical and Experimental Optometry1 (2019): 3-17.
5. Guggenheim JA., et al. “Genome-wide association studies of refractive error and myopia, lessons learned, and implications for the future”. Investigative Ophthalmology and Visual Science3 (2019): 1506-1512.
6. Rose KA., et al. “Outdoor activity reduces the prevalence of myopia in children”. Ophthalmology8 (2008): 1279-1285.
7. Huang HM., et al. “The association between near work activities and myopia in children—A systematic review and meta-analysis”. PLOS ONE10 (2015): e0140419.
8. Chen Y., et al. “Association of digital screen use with myopia: A systematic review and meta-analysis”. Acta Ophthalmologica6 (2019): 570-581.
9. Charm J and Cho P. “High myopia-partial reduction orthokeratology (HM-PRO): A 2-year randomized study”. Optometry and Vision Science6 (2013): 530-539.
10. Chia A., et al. “Atropine for the treatment of childhood myopia: Safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2)”. Ophthalmology2 (2012): 347-354.
11. Walline JJ., et al. “Myopia control with orthokeratology contact lenses in Spain: ReVision study”. Eye and Contact Lens5 (2017): 338-343.
12. Lin Z., et al. “The China children's refractive error study: Design and baseline data”. Ophthalmic Epidemiology2 (2014): 114-120.